About
Technology
Issues
FAQ
Links
Official Page
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.